Trade INVA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Innoviva, Inc. (INVA) is trading at US$20.95, down 0.07% today as of Aug 28, 12:17 EDT. The company has a market capitalisation of US$1.52B. Over the past 52 weeks, INVA has traded between US$16.52 and US$25.15. On Syfe you can trade INVA with $0 commission and add it to your watchlist.
| Previous close | US$20.96 |
|---|---|
| Market cap | US$1.52B |
| P/E ratio | 8.87 |
| 52-week range | US$16.52 – US$25.15 |
| Volume | 488.06K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Innoviva, Inc.
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Year: 2004
Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro
Jun 16, 12:21 PM · MT Newswires
-- Earnings Flash (INVA) Innoviva, Inc. Reports Q1 Revenue $98.0M, vs. FactSet Est of $101.6M
May 6, 8:24 PM · MT Newswires
Innoviva, Inc. (INVA) stock is trading at US$20.95, -0.07% from the previous close of US$20.96.
The market cap for Innoviva, Inc. (INVA) stock is approximately US$1.52B.
The price-to-earnings ratio for Innoviva, Inc. (INVA) is 8.87, based on the latest reported earnings.
The 52-week high for Innoviva, Inc. (INVA) stock is US$25.15.
The 52-week low for Innoviva, Inc. (INVA) stock is US$16.52.
Innoviva, Inc. (INVA) does not currently pay a dividend.
Stay on top of INVA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
